Abstract
Materials and Methods
Results
Conclusions
ACKNOWLEDGEMENTS
Notes
Disclosures: Professor Geoffrey Hackett has received honoraria for acting as a speaker for Bayer plc who provided the grant. Professor Sudarshan Ramachandran has received educational grants to attend meetings and honoraria for serving as a speaker for Besins Health Care Ltd. Professor Geoffrey Hackett has spoken at various national and international meetings on testosterone and PDE5I treatments in men. These companies and activities had no influence on this project. And other authors have no potential conflicts of interest to disclose.
Author Contribution: Full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis: Hackett G, Ramachandran S. Study concept and design: Hackett G, Cole N. Analysis and interpretation of data: Hackett G, Ramachandran S, Mulay A, Strange RC. Drafting of the manuscript: Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S.
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Fig. 1
Patient recruitment for the BLAST randomised controlled trial (RCT). Of the 857 men screened 199 men took part in the BLAST RCT evaluating changes in metabolic parameters and sexual function scores after 30 weeks of testosterone replacement therapy compared with placebo. IIEF: international index of erectile function, TT: total testosterone, SHBG: sex hormone-binding globulin, HbA1c: hemoglobin A1c, PSA: prostate specific antigen, T2DM: type 2 diabetes, FT: free testosterone, TU: testosterone undecanoate, P: placebo, T: testosterone.
![wjmh-38-68-g001](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-g001.jpg)
Fig. 2
Changes in hemoglobin A1c (HbA1c) (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. The number of drugs prescribed to control diabetes in each group is also shown. SE: standard error.
![wjmh-38-68-g002](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-g002.jpg)
Fig. 3
Change in weight (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. SE: standard error.
![wjmh-38-68-g003](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-g003.jpg)
Fig. 4
Change in waist circumference (WC) (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. SE: standard error.
![wjmh-38-68-g004](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-g004.jpg)
Fig. 5
Changes in international index of erectile function (IIEF) erectile function (EF) (low testosterone [low T]/treated and low T/untreated men) during the 30 week BLAST randomised controlled trial (RCT), open-label (30–82 weeks), and normal care (post 82 weeks) phases in men recruited to the BLAST RCT and those screened with baseline IIEF EF scores. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups. SE: standard error.
![wjmh-38-68-g005](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-g005.jpg)
Table 1
Baseline characteristics of the study group when classified by patient groups based on TRT
![wjmh-38-68-i001](/upload/SynapseXML/2074wjmh/thumb/wjmh-38-68-i001.jpg)